linjc16/ctgov huggingface dataset:
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy

Study Overview
=================
Brief Summary
-----------------
to determine the values of imaging and genetic biomarkers for prediction of tumor aggressiveness and prognosis in patient with early stage lung adenocarcinoma to Identify unique copy number alteration in patient with early stage lung adenocarcinoma to evaluate the long-term change of ground-glass nodule combined with lung adenocarcinoma to suggest a guideline for planning an appropriate follow-up examination and management

Official Title
-----------------
Prospective Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy

Conditions
-----------------
Lung Adenocarcinoma

Intervention / Treatment
-----------------
* Other: CT, PET, copy number alteration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A. Clinically and radiologically suspected lung adenocarcinoma B. Newly-diagnosed Stage I or II from the clinical work up including PET/CT C. Performance status of 0 to 1 on the ECOG scale D. Age 20 years or older E. Able to tolerable DECT imaging required by protocol F. Able to give study-specific informed consent Exclusion Criteria: A. Prior malignancy B. planning of Definitive RTx 나 neoadjuvant CCRTx C. Poor cardiopulmonary reserve

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| early stage lung adenocarcinoma<br> | Other: CT, PET, copy number alteration<br>* Duel-energy CT, PET, copy number alteration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of tumor aggressiveness |  | five years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognosis of early stage lung adenocarcinoma following operation |  | five years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung adenocarcinoma, prognosis, tumor aggressiveness, imaging biomarker, genetic biomarker
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.

Conditions
-----------------
Breast Cancer Patients in Premenopausal, Estrogen and/or Progesterone Receptor Positive

Intervention / Treatment
-----------------
* Drug: toremifene or tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Breast cancer Received standard treatment (chemotherapy, operation, or radiotherapy) premenopausal estrogen and/or progesterone receptor positive Exclusion Criteria: Metastatic tumors During pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tamoxifen<br>tamoxifen,20mg/day | Drug: toremifene or tamoxifen<br> <br> |
| Experimental: toremifene<br>toremifene,60mg/day | Drug: toremifene or tamoxifen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival outcomes: disease free survival |  | up to 5 years | 
| 5-year overall survival |  | up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| side effects effects of therapies | the primary safety measures are Hepatic function and blood lipid | Follow-up period,up to 5 years | 
| Incidence of adverse events | Adverse events including hot flashes, irregular menses and others. | follow-up period, up to 5 years |
The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy

Study Overview
=================
Brief Summary
-----------------
The aim of this study was evaluated the feasibility of bilateral intermediate cervical plexus blockade to be anesthesia for simple thyroid/parathyroid surgery.

Detailed Description
-----------------
Bilateral intermediate cervical plexus blocks have been reported for thyroid/parathyroid surgery. This technique combined with intravenous sedation has used with safety in patients undergoing simple thyroid or parathyroid surgery. Simple surgery is defined as the thyroid conditions are not cancer, redo or substernal goiter.

Official Title
-----------------
The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study

Conditions
-----------------
Parathyroid Adenoma, Thyroid Nodule

Intervention / Treatment
-----------------
* Procedure: Bilateral intermediate cervical plexus block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient underwent thyroid/parathyroid surgery under nerve blocks and sedation Exclusion Criteria: incomplete opioid consumption or pain score record.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Conversion to general anesthesia | inability to operate under nerve block and sedation | during operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| opioid usage | fentanyl consumption | intraoperative | 
| dypnea | phrenic nerve paralysis | intraoperative | 
| pain score within 24 hours | numerical rating score | within 24 hours postoperative | 
| complications | local anesthetic systemic toxicity | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intermediate cervical plexus block
Recurrence Rate of Mini-SLET vs. Limbal-Conjunctival Autograft in Primary Pterygium Excision

Study Overview
=================
Brief Summary
-----------------
To study the efficacy and safety of amniotic membrane transplantation as an adjunctive therapy after surgical excision of primary pterygium and compare the clinical outcomes with conjunctival autograft

Detailed Description
-----------------
Prospective Randomized Blind Clinical Trial Sixty-four eyes of 64 patients with primary nasal pterygium have been operated by two surgeons (E. G-H, A. N-C). All patients are randomized to undergo Mini-SLET or limbal-conjunctival autograft transplantation as an adjuvant therapy after pterygium excision. Four eyes were treated with Mini-SLET(group 1), and 26 eyes have been operated with conjunctival autograft (group 2). Patients will be followed up at 1 day, 1 week, 1, 3, 6, 9 and 12 months postoperation. The main outcome measurement was a recurrence rate after surgery.

Official Title
-----------------
Recurrence Rate of Mini-SLET (Simple Limbal Epithelial Transplantation) vs. Limbal-Conjunctival Autograft in Primary Pterygium Excision

Conditions
-----------------
Pterygium of Conjunctiva and Cornea

Intervention / Treatment
-----------------
* Procedure: Pterygium Excision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary nasal pterygium > 2mm Exclusion Criteria: Pregnant Previous ocular surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mini-SLET<br>Simple Limbal Epithelial Transplantation | Procedure: Pterygium Excision<br>* Pterygium excision is the first step for repair<br>* Other names: Mini-SLET;|
| Experimental: Limbal-Conjunctival Autograft<br>Patients treated with limbal-conjunctival autograft | Procedure: Pterygium Excision<br>* Pterygium excision is the first step for repair<br>* Other names: Mini-SLET;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence rate | Regrowth of pterygium | one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crosslinking
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Study Overview
=================
Brief Summary
-----------------
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the FVII gene in patients previously exposed to rFVIIa analogue.

Official Title
-----------------
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial

Conditions
-----------------
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent obtained before collection of saliva samples Previous participation in adept™2 trial with 5 or more exposure days to rFVIIa analogue

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Collection of specimen<br> | Other: No treatment given<br>* For patient convenience, genetic material will be collected in the form of saliva samples.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of HLA Type | HLA typing includes up to 8 different HLA types (HLA-DRB1/B3/B4/B5, DPA1/B1 and DQA1/B1) and their most likely alleles. Number of participants with most likely HLA allele are reported. | Up to 12 months | 
| Determination of Polymorphisms in the FVII Gene | Determination of polymorphisms in the FVII gene in patients who participated in the completed NN1731-3562 (adeptTM2) phase 3 trial, with 5 or more exposure days to trial product rFVIIa analogue and/or rFVIIa. | Up to 12 months |
Decision Aid Development for Smokers

Study Overview
=================
Brief Summary
-----------------
A decision aid tool will be developed using participatory research approach. The decision aid will be targeted to cigarette smokers scheduled for elective surgery.

Official Title
-----------------
Decision Aid Development for Cigarette Smokers Undergoing Surgery: Specific Aim 1

Conditions
-----------------
Smoking, Elective Surgery

Intervention / Treatment
-----------------
* Other: Decision aid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Current cigarette smoker having elective surgery at Mayo Clinic Rochester and is scheduled to be seen at Preoperative Evaluation Center.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score on Decisional Conflict Scale and COMRADE Scale |  | Perioperative period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoking cessation, Smoking, Tobacco
Buccinator Myomucosal Flap With Furlow Palatoplasty and VPI

Study Overview
=================
Brief Summary
-----------------
Nasopharyngoscopic examination of the 20 patients with secondary VPI following 2 flap palatoplasty will be done for visualization of the velopharyngeal port, allowing assessment of the pattern and grade of velopharyngeal closure during speech and the presence or absence of a velopharyngeal gap and after VPI repair by Buccinator myomucosal flap with Furlow palatoplasty

Official Title
-----------------
Anatomical Restoration Cleft Palate Technique (ARC) for Secondary Velopharyngeal Incompetence Post Cleft Palate Repair

Conditions
-----------------
Velopharyngeal Insufficiency

Intervention / Treatment
-----------------
* Procedure: Buccinator myomucosal flap with Furlow palatoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5-6 years old children with previous treated complete cleft palate with 2 flap palatoplasty technique, nonsyndromic. lip and palate repair performed by one craniofacial surgeon Exclusion Criteria: Patients with syndromic cleft lip. Bilateral cleft lip Patient older younger 5 years. Associated Cardiac anomalies. Any systemic condition

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Buccinator myomucosal flap with Furlow palatoplasty<br> | Procedure: Buccinator myomucosal flap with Furlow palatoplasty<br>* Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| grade of velopharyngeal closure during speech | Nasopharyngoscopic examination of the patients with secondary velopharyngeal insufficiency ( VPI) following two flap palatoplasty cleft palate repairs will be done for assessment of velopharyngeal closure grade during speech after VPI repair by Buccinator myomucosal flap with Furlow palatoplasty | immediate postoperative |
Post-hospitalisation Nutritional Support and Gait Speed in COPD

Study Overview
=================
Brief Summary
-----------------
To determine the feasibility of delivering different community nutritional interventions to chronic obstructive pulmonary disease (COPD) patients at moderate or severe risk of malnutrition following a hospitalisation for an acute exacerbation of COPD.

Official Title
-----------------
The Effect of Nutritional Support on Gait Speed Following Hospitalisation for Acute Exacerbation of COPD

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive, Respiratory Tract Diseases, Lung Diseases, Obstructive, Bronchitis, Chronic, Pulmonary Emphysema

Intervention / Treatment
-----------------
* Dietary Supplement: Food fortification
* Dietary Supplement: Oral Nutritional Supplements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to consent Patients at moderate or severe risk of malnutrition Adults over the age of 40 Hospitalised with an AECOPD Exclusion Criteria: Receiving long term parental or enteral nutrition Inability to swallow or difficulty liquids Lactose intolerance, galactosaemia, cow's milk protein allergy or intolerance Co-existing active cancer, progressive neurological condition or active GI disorder. Receiving palliative care with expectation of death within 3 months Cognitive dysfunction or unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Food Fortification<br>Food Fortification | Dietary Supplement: Food fortification<br> <br> |
| Experimental: Oral Nutritional Supplements<br>Oral Nutritional Supplements - Fortisip Compact | Dietary Supplement: Oral Nutritional Supplements<br> <br> * Other names: Fortisip Compact, Nutricia Clinical;|
| No Intervention: Usual Care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in four-metre gait speed (m/s) following nutritional support |  | Change from baseline to 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in weight (kg) following nutritional support |  | Change from baseline to 12 weeks | 
| Change in fat free mass (kg) as measured by bioelectrical impedence following nutritional support |  | Change from baseline to 12 weeks | 
| Change in fat free mass index (kg/m2) as measured by bioelectrical impedence following nutritional support |  | Change from baseline to 12 weeks |
Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).

Detailed Description
-----------------
The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy. However, evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients. Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent. In particular, the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk, such as preserved left ventricular systolic function or single-vessel disease. Therefore, we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI.

Official Title
-----------------
Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Conditions
-----------------
Actue Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consecutive patients 18 years of age or older; patients diagnosed as ACS(including STEMI、NSTEMI and UA) by doctor at discharge; patients undergoing primary PCI. Exclusion Criteria: missing beta-blocker information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause death | The primary outcome was all-cause death during follow up. | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | Secondary outcomes included major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction, stroke, any revascularization during follow-up | 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Actue Coronary Syndrome, Beta-Blocker, Percutaneous Coronary Intervention